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Abstract
Objective To compare the prognosis in women with interval breast
cancer (cancer detected after a normal screening mammogram and
before the next scheduled mammogram) with breast cancer detected
among women not yet invited to mammography screening
(non-screened).
Design Population based observational study.
Setting Norwegian breast cancer screening programme, implemented
in different counties from 1996 to 2005.
Participants 7116 women with a diagnosis of breast cancer at age 50
to 72 years; 1816 had interval breast cancer and 5300 had a diagnosis
of breast cancer but had not yet been invited to screening.
Main outcome measures Characteristics of the breast tumours, and
survival of the women using Kaplan Meier curves and multivariable Cox
proportional hazard models.
Results Although interval cancers on average were slightly larger than
the cancers in women not invited to screening, the histological type or
status of axilliary lymph nodes did not differ noticeably between the two
groups. Among interval cancers, there were no appreciable trends in
size, nodal status, grade, or hormone receptor positivity associated with
time since the last normal mammogram as a marker of growth rate. After
10 years of follow-up, the survival rates were 79.1% (95% confidence
interval 75.4% to 82.3%) among women with interval cancers and 76.8%
(75.3% to 78.2%) among women in the non-screened cancer group
(hazard ratio 0.98, 95% confidence interval 0.84 to 1.15; P=0.53).
Analyses stratified by time since last normal mammogram, age at
diagnosis, or screening round showed similar results.
Conclusion The prognosis of women with interval breast cancers was
the same as that of women with breast cancers diagnosed without
mammography screening.
Introduction
When mammography screening programmes are fully
implemented,intervalcancerscompriseasubstantialproportion
of incident breast cancers. Interval cancers may have been
overlooked at the last mammography examination or become
apparent because they grew so rapidly that the detectable
preclinical phase (sojourn time) was shorter than the screening
interval.
Because interval breast cancers in some studies on average are
larger,
1 2 of a more advanced stage,
1 and express proliferative
markers more than screen detected tumours,
1 3 it has been
suggested that prognosis of interval breast cancers is poorer
thanthatofscreendetectedbreastcancers.
3However,prognostic
studies may be misleading when comparing interval breast
cancers with screen detected breast cancers because the screen
detected breast cancers are affected by length bias sampling,
lead time bias, and overdiagnosis bias. Therefore the valid
comparison group for assessment of prognosis in women with
interval breast cancers is non-screen detected cancers among
women not invited to mammography screening, which are
unaffected by the biases that screening entails. Comparisons
with historical groups, as in many previous studies, may also
lead to confounding because survival from breast cancer has
improvedovertime.
4 5Onlyafew,smallstudieshavecompared
the survival of women with interval breast cancer with those
with non-screen detected breast cancer, with inconsistent
findings.
6-13
In this population based study we took advantage of the
nationwide breast cancer screening programme in Norway,
whichhasbeengraduallyimplementedoveranineyearperiod.
13
This staggered roll out allowed a comparison between women
with interval breast cancer and those with breast cancer
Correspondence to: M Kalager Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, Boston,
USA mkalager@hsph.harvard.edu
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e7536 doi: 10.1136/bmj.e7536 (Published 16 November 2012) Page 1 of 10
Research
RESEARCHdiagnosed within the same period but before they had been
invited to mammography screening.
We investigated whether breast cancers detected in the interval
after a normal mammography screening result but before the
next scheduled screening are more lethal and thus may need
more aggressive treatment than non-screen detected breast
cancers.
Methods
Breast cancer screening programme
Since 1951, reporting of cancer diagnoses to the nationwide
Cancer Registry of Norway has been compulsory by national
legislation.Patientsareidentifiedintheregistrybytheirunique
nationalregistrationnumber,assignedtoallresidentsinNorway
and including date of birth. The cancer registry has maintained
nearly 100% completeness for solid cancers, including breast
cancer.
14 15
In 1996 the Norwegian breast cancer screening programme
startedinfourcountiesandthenexpandedgradually,countyby
county, over the course of nine years.
4 13 Since 2005, all women
in Norway aged 50-69 years are invited to mammography
screening every two years. The Central Population Register of
Norwayidentifieswomeneligibleforscreeningbytheirnational
registration number. Invitations are posted to each eligible
woman, suggesting an appointment time.
16 Two radiologists
independentlyreadtwoviewmammograms(craniocaudalviews
and mediolateral oblique views) in accordance with European
guidelinesforqualityassurance,
17whichareclassifiedaccording
to a five point interpretation scale reflecting the probability of
cancer.
18 The decision as to whether further diagnostic
examinations are necessary is based on the consensus of two
experienced radiologists. After this final decision, no further
diagnostic tests are done before the next scheduled screening
invitation.
For the purpose of the study we classified women as having
interval cancer if breast cancer was diagnosed within two years
and two months of the last normal screening mammogram but
before invitation to the next screening. Hence the cohort of
women with interval cancers included only those who were
invited participants in the screening programme but had
non-screened detected breast cancer. For the present analysis
we extended the screening interval by two months because we
retrieved date of diagnosis from two databases that were not
completely in agreement about the date; the additional two
months made it possible to include all women classified as
having interval cancers in the screening database. Among
women who reach the upper age limit of 70 years for invitation
to screening, we defined interval cancers as those diagnosed
withintwoyearsandtwomonthsafterthelastnormalscreening
examination.
Wefurtherdividedthecancersintogroups(sixmonthintervals)
accordingtothetimebetweenthedateofdiagnosisandthedate
of the last normal screening examination, to explore the
hypothesis that more rapidly growing cancers arising shortly
after a normal screening mammogram have a poorer
prognosis.
8 19 20 Owing to increased experience by the
radiologists,screeningsensitivitymightincreasewithincreasing
screeningrounds.Underthisassumptionthenumberofcancers
overlooked at screening mammography should decline with
time since start of the screening programme. Thus a growing
proportion of cancers detected between scheduled screenings
should be true interval cancers. If true interval cancers were a
moreaggressivesubtypeofbreastcancers,intheorythesurvival
of women with these tumours might be worse than for those
whosebreastcancerisoverlooked,andwithincreasingscreening
rounds and more experience the prognosis would be worse. We
therefore carried out a secondary analysis restricted to interval
breast cancers stratified by screening round.
Study population
From the cancer registry database we retrieved information on
date of diagnosis, age at diagnosis, county of residency,
classificationofthecanceraccordingtothepathologicaltumour,
node, metastases (pTNM) classification (International Union
Against Cancer guidelines),
21 and tumour stage in all women
with a first diagnosis of invasive breast cancer at age 50 to 72
years in Norway between 1 January 1996 and 31 December
2006.ThestageofbreasttumouriscodedasI(localisedcancer),
II (regional cancer), III (cancer fixed to the skin or the chest
wall), or IV (cancer with distant metastases). To determine
whether a diagnosis was made before or after invitation to
screening we linked data on all the women to the screening
database at the cancer registry. We then further categorised
women with breast cancer diagnosed after invitations to
screening as interval cancers if they met our criteria.
Fromthescreeningdatabasewefurtherretrieveddataontumour
grade (based on the Nottingham grading system, I-III
22);
oestrogen and progesterone receptor status
21; pTNM
classification; and dates of invitation and attendance to the
screeningprogramme.Weclassifiedoestrogenandprogesterone
receptorsaspositive(≥10%positivestaining)ornegative(<10%
positive staining). These data were not available from the
registry’s database and as a result are not available for women
not invited to mammography screening. We defined screening
rounds by county rather than by individual women. The
follow-up period was from 1 January 1996 to 31 December
2006. Linkage to the Central Population Register of Norway
and the National Death Register allowed censoring at date of
emigration or death. For the purpose of this study we defined
two study cohorts:
• Interval cancer group—comprising all women with a first
diagnosis of invasive breast cancer during the interval
between two screening rounds or breast cancer diagnosed
within two years and two months after the date of the last
normal examination in the breast cancer screening
programme between 1996 and 2006.
• Non-screened cancer group—comprising all women with
a first diagnosis of invasive breast cancer who had not yet
been invited to the breast cancer screening programme
between 1996 and 2006.
Statistical analyses
WeusedthePearsonχ
2testtocomparetheintervalcancergroup
with the non-screened cancer group according to the
characteristics of the tumours, and we used a linear regression
model to test trends across time intervals from a last normal
screeningresult.Usinglifetabletechniqueswecalculatedbreast
cancer specific survival rates and overall survival rates,
illustrated by Kaplan-Meier plots, and we compared these rates
usingthelogranktest.Censoringoccurredatdateofemigration,
date of death from causes other than breast cancer, or the end
of the follow-up period (31 December 2006), whichever came
first.
Hazard ratios were calculated using Cox proportional hazard
models. We used likelihood ratio statistics to compare groups.
We adjusted for age at diagnosis by four categories: 50-54,
55-59, 60-64, and 65-72 years. We further adjusted for time
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result. Because survival from breast cancer differed between
counties, we adjusted for county and time trends by including
county specific trend variables in the model.
4 We did not adjust
for stage at diagnosis owing to the likelihood of stage
migration,
23 but we carried out further analyses stratified by
stage. For interval cancers only, we carried out secondary
analyses to examine the association and possible interaction of
time since last normal screening result and screening round.
The proportional hazards assumption was tested by both
graphicalmethodsandSchoenfeldresidualsanditwasachieved.
All test statistics were two tailed, and we considered P values
<0.05 to be significant. Calculations were done with the
statistical package Stata 10.0.
Results
Table 1⇓ summarises the characteristics of the 1816 women in
the interval cancer group and the 5300 women in the
non-screened cancer group. The mean age at diagnosis was
similar between the groups, whereas the mean follow-up time
was 3.6 (SD 2.6, maximum 10.6) years for the interval cancer
group and 6.3 (SD 3.0, maximum 11.2) years for the
non-screened cancer group. Compared with the non-screened
cancer group, the interval cancer group had a slightly higher
proportionoflobularcancers,largetumours(>20mmdiameter),
negative axillary lymph nodes, and stage II rather than stage I
disease (table 1). The proportion of women who had a sentinel
node biopsy was about three times higher in the interval cancer
group than in the non-screened cancer group. Adjuvant
tamoxifenwasgivento701(38.6%)ofthewomenintheinterval
cancer group and 1912 (36.1%) in the non-screened cancer
group.
Table 2⇓ shows the characteristics of interval breast cancers by
sixmonthintervalsfromdateofthelastnormalscreeningresult.
The number of interval cancers increased with increasing time
after a normal result. The mean tumour diameter for interval
cancers increased by only 2.2 mm during the two years after a
normal screening result (P for trend 0.03). There was no
evidence that any other tumour characteristics varied by time
since last normal screening result. The results were essentially
the same with shorter intervals (data not shown).
Cumulative breast cancer survival did not differ between the
two groups (P=0.53, fig 1⇓). After 10 years of follow-up, the
survival rate among women with interval cancers was 79.1%
(95% confidence interval 75.4% to 82.3%) and among women
with cancers in the non-screened group was 76.8% (75.3% to
78.2%). Five year and 10 year age adjusted survival estimates
by tumour stage at diagnosis were also similar for the study
groups (data not shown). Cumulative overall survival did not
differ between the two groups (P=0.67, fig 2⇓). After 10 years
of follow-up, the overall survival rate among women with
intervalcancerswas72.6%(68.5%to76.3%)andamongwomen
with cancers in the non-screened group was 68.9% (67.3% to
70.5%).
Table 3⇓ shows data derived from Cox proportional hazards
model analyses of age at diagnosis and time since last normal
screening result as possible determinants of a difference in
survival between the cancer groups. Breast cancer specific
mortality did not differ between the interval cancer group and
the non-screened cancer group (hazard ratio 0.98, 95%
confidence interval 0.84 to 1.15, P=0.81). There was no
association between time since last normal screening result and
survival (table 3). The results did not change after adjustment
for age at diagnosis, year of diagnosis, and county of residency
(data not shown).
Asecondaryanalysisrestrictedtointervalcancersandstratified
by screening round showed no evidence that survival was
associated with screening round, either overall or after
stratification by time since last normal screening result (table
4⇓). Furthermore, after up to four screening rounds, the
incidence of interval cancers was not associated with number
ofscreeningrounds.Whentheanalysiswasrestrictedtocounties
withaminimumoftwoyearsandtwomonthsoffollow-upafter
examination,theincidenceper100000womanyearswas163.4
in the first screening round, 162.5 in the second, 193.3 in the
third, and 166.5 in the fourth.
Discussion
Thesurvivalofwomenwithadiagnosisofintervalbreastcancer
after a normal mammogram is similar to that of women with
breast cancer diagnosed before an invitation to a breast cancer
screening programme. Contrary to our a priori hypothesis, we
found no evidence that tumours that become clinically evident
shortly after the last normal screening result were more
aggressive in terms of larger size, higher grade, higher
proportionofnodemetastases,orlowersurvivalthannon-screen
detected breast cancers. Among the interval cancers, average
tumour size increased slightly over time since last normal
screening result, but no other characteristics of the tumour or
risk of dying from breast cancer varied by time since the last
normal screening result.
Althoughseveralinvestigatorshaveexaminedwhetherinterval
cancersareassociatedwithpoorsurvival,controversyremains.
Previousstudieshavebeenlimitedbysmallsamplesize
7-10 20 24-27;
invalidcomparisongroups,notablyscreendetectedcancers
9 25-27;
or use of historical controls.
8 11 12 Furthermore, the findings in
these studies were inconsistent. Analysis based on randomised
trials of mammography screening found that survival with
intervalcancerswassimilar,
7 27better,
20orpoorer
24thansurvival
with non-screen detected cancers. Although studies based on
randomised trials have a valid comparison group, chance could
explaintheinconsistentfindingsbecausethesamplesizesinall
the studies were limited (<100 interval cancers).
7 20 24 28
In observational studies, where survival rates of women with
intervalcancersarecomparedwiththoseofwomenwithscreen
detected cancers or historical controls, or both, survival
associatedwithintervalcancerswassimilartothatofnon-screen
detected cancers in some studies,
9 11 26 worse in others,
14 and
worse than screen detected cancers but better than clinically
detected cancers in studies where interval cancers were
compared with both screen detected and historical
controls.
10 12 14 20 However, in these studies comparisons are
likely to be confounded by lead time, overdiagnosis, and
temporal trends in survival from breast cancer.
4 5 11 The only
remaining alternative is contemporary patients unaffected by
mammography screening. Theoretically, the ideal comparison
group would be breast cancer diagnosed among unscreened
women who would have attended screening if they had been
invited.Suchadesignwouldeliminatethepotentialconfounding
by factors that affect both attendance and outcome. However
such a study is not feasible; to our knowledge there is limited
reason in the Norwegian healthcare system to believe in any
substantial bias through this mechanism, and this bias, if it
exists, would affect only a small proportion of incident breast
cancers because the attendance rate in the Norwegian
mammography screening programme is high (77% among
invited women). Overall survival was similar between women
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(fig 2), indicating that the results were not influenced by the
potential selection bias among women with interval cancer.
Strengths and limitations of this study
To date, this population based study is the largest in the area of
interval breast cancer and has the longest follow-up. The
staggered introduction of the screening programme and the
comparison of interval cancers with non-screen detected breast
cancer avoided major biases.
This study, however, has several potential limitations. Because
only a few of the interval cancers had been individually
reviewed, we were unable to distinguish true interval cancers
fromthoseoverlookedwhenthemammogramswereexamined.
InapreviousreviewinNorwaycomprisingaround200interval
cancers, 35% were reinterpreted as overlooked, 23% showed
minimal signs of malignancy, and 42% were true interval
cancers,
29 30 similar to the results of other studies.
31 32 The
overlookedtumourswereonaveragelargerandmoreoftennode
positive than the true interval cancers. This could be because
the affected women were reassured by the last normal
mammogramresultandthereforedelayedseekingmedicalcare.
However, other studies have found no differences in survival
between interval cancers classified as true or overlooked.
33 34
In each Norwegian county, introduction of the breast cancer
screening programme was preceded by the establishment of
specialised multidisciplinary teams.
4 13 The goal of these teams
wastoprovidethebestpossiblemanagementofallwomenwith
newly diagnosed breast cancers in the county, regardless of
whetherthecancerwasdiagnosedbymammographyscreening.
We have shown previously that this optimised management
entailedasubstantialreductioninmortalityalsoamongwomen
withbreastcancernotdiagnosedbymammographyscreening.
4 13
Owing to the design of our current study, only women with
interval cancers were managed by multidisciplinary teams.
Hence it is conceivable that better treatment eliminated
altogether a poorer prognosis among the women with interval
cancers than among those with non-screen detected cancers.
The possible influence of such confounding could not be tested
in our study because it would have required more detailed
individual data on prognostic factors, treatment, and overall
management. However, the similar proportion of women in
eachgroupwhoreceivedadjuvanttamoxifentreatmentsprovides
some reassurance against a major confounding.
Conclusions
Weconcludethattumoursassociatedwithintervalbreastcancers
are more likely to be larger than those diagnosed in the absence
of mammography screening; but they have strikingly similar
survival outcomes. Furthermore, the characteristics of the
tumours (except for an increase of 2.2 mm in diameter) and the
prognosis of women with interval cancers were not associated
with time since last mammography. These findings challenge
the theory of a strong correlation between growth rate and
metastaticbehaviour.Ourstudyprovidesnocompellingsupport
formoreaggressiveprimarytreatmentofintervalbreastcancers
than non-screen detected cancers with similar prognostic
features.
14
Contributors: MK designed the study and did the statistical analysis.
MK had full access to the data in the study and takes responsibility for
the integrity of the data and the accuracy of the data analysis. MK, RT,
MB, and HOA interpreted the data and cowrote and edited the paper.
Funding: This study was funded by research grants from the Norwegian
Research Council and Frontier Science. The funders had no role in the
design and conduct of the study; the collection, management, analysis,
and interpretation of the data; and the preparation, review, or approval
of the manuscript.
Competing interests: All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf (available on
request from the corresponding author) and declare: no support from
any organisation for the submitted work; no financial relationships with
any organisations that might have an interest in the submitted work in
the previous three years; no other relationships or activities that could
appear to have influenced the submitted work.
Ethical approval: The research protocol was approved by the Norwegian
Social Science Data Services 2008. Individual informed consent was
not requested.
Data sharing: No additional data available.
1 Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, et al. A basal epithelial
phenotype is more frequent in interval breast cancers compared with screen detected
tumors. Cancer Epidemiol BiomarkersPrev 2005;14:1108-12.
2 Gilliand FD, Joste N, Stauber PM, Hunt WC, Rosenberg R, Redlich G, et al. Biologic
characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst
2000;92:743-9.
3 Sihto H, Lundin J, Lehtimäki T. Molecular subtypes of breast cancer detected in
mammography screening and outside of screening. Clin Cancer Res 2008;14:4103-10.
4 Kalager M, Haldorsen T, Bretthauer M, Hoff G, Thoresen SO, Adami HO. Improved breast
cancer survival following introduction of an organized mammography screening program
among both screened and unscreened women: a population-based cohort study. Breast
Cancer Res 2009;1:R44.
5 Zackrisson S, Janzon L, Manjer J, Andersson I. Improved survival rate for women with
interval breast cancer—results from the breast cancer screening programme in Malmö,
Sweden 1976-1999. J Med Screen 2007;14:138-43.
6 Wang H, Bjurstam N, Bjørndal H, Braaten A, Eriksen L, Skaane P, et al. Interval cancers
in the Norwegian breast cancer screening program: frequency, characteristics and use
of HRT. Int J Cancer 2001;94:594-8.
7 Holmberg LH, Adami HO, Tabar L, Bergström R. Survival in breast cancer diagnosed
between mammographic screening examinations. Lancet 1986;2:27-30.
8 Brekelmans CT, Peeters PH, Deurenberg JJ, Collette HJ. Survival in interval breast cancer
in the DOM screening programme. Eur J Cancer 1995;31:1830-5.
9 Schröen AA, Wobbes T, van der Sluis RF. Interval carcinomas of the breast: a group with
intermediate outcome. J Surg Oncol 1996;63:141-4.
10 Collins S, Woodman CBJ, Threlfall A, Prior P. Survival rates from interval cancers in NHS
breast screening programme. BMJ 1998;316:832-3.
11 Bordás P, Jonsson H, Nyström L, Lenner P. Survival from invasive breast cancer among
interval cases in the mammography screening programmes of northern Sweden. Breast
2007;16:47-54.
12 Lawrence G, O’Sullivan E, Kearins O, Tappenden N, Martin K, Wallis M. Screening
histories of invasive breast cancers diagnosed 1989-2006 in the West Midlands, UK:
variation with time and impact on 10-year survival. J Med Screen 2009;16:186-92.
13 Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on
breast-cancer mortality in Norway. N Engl J Med 2010;363:1203-10.
14 Larsen IK, Småstuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data
quality at the cancer Registry of Norway: an overview of comparability, completeness,
validity and timeliness. Eur J Cancer 2009;45:1218-31.
15 Tingulstad S, Haldorsen T, Norstein J, Hagen B, Skjeldestad FE. Completeness and
accuracy of registration of ovarian cancer in the cancer registry of Norway. Int J Cancer
2002;98:907-11.
16 Wang H, Kåresen R, Hervik A, Thoresen S. Mammography screening in Norway: results
from the first screening round in four counties and cost effectiveness of a modeled
nationwide screening. Cancer Causes Control 2001;12:39-45.
17 Perry N, Broeders M, de Wolf C. European guidelines for quality assurance in breast
cancer screening and diagnosis. 2nd edn. Office for official publications of the European
Communities, 1996.
18 Erzaas A. Quality assurance manual of the norwegian breast cancer screening program
[Norwegian]. The Cancer Registry of Norway; 2003. www.kreftregisteret.no.
19 Cowan WK, Angus B, Gray JC, Lunt LG, Al-Tamimi SR. A study of interval breast cancer
within the NHS breast screening programme. J Clin Pathol 2000;53:140-6.
20 Frisell J, von Rosen A, Wiege M, Nilsson B, Goldman S. Interval cancers and survival in
a randomised breast cancer screening trial in Stockholm. Breast Cancer Res Treat
1992;24:11-6.
21 Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging
manual, 7th edn. Springer-Verlag, 2010.
22 Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary
breast cancer. Breast Cancer Res Treat 1992;22:207-19.
23 Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and
new diagnostic techniques as a source of misleading statistics for survival in cancer. N
Engl J Med 1985;312:1604-8.
24 Andersson I, Aspgren K, Janzon L, Landberg T, Lindholm K, Linell F, et al. Mammographic
screening and mortality from breast cancer: the Malmö mammographic trial. BMJ
1988;29:943-8.
25 Vitak B, Stål O, Månson JC, Thomas BA, Arnesson LG, Ekelund L, et al. Interval cancers
and cancers in non-attenders in the Östergötland mammographic screening programme.
Duration between screening and diagnosis, s-phase fraction and distant recurrence. Eur
J Cancer 1997;33:1453-60.
26 Rayson D, Payne JI, Abdolell M, Barnes PJ, MacIntosh RF, Foley T, et al. Comparison
of clinical-pathologic characteristics and outcomes of true interval and screen-detected
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e7536 doi: 10.1136/bmj.e7536 (Published 16 November 2012) Page 4 of 10
RESEARCHWhat is already known on this topic
Previous randomised trials on mammography screening found that interval breast cancers were associated with similar, better, or poorer
survival compared with non-screened breast cancers
These inconsistent findings can be explained by small sample sizes (<100 interval cancers)
Observational studies suggested that interval cancers were associated with poor survival but were limited by small sample size and
invalid comparison groups
What this study adds
Interval breast cancers were more likely to be larger than breast cancers diagnosed in the absence of mammography screening
Survival outcomes between the two cancer groups were, however, strikingly similar
Our study provides no compelling support for more aggressive primary treatment of interval breast cancers than non-screening cancers
with similar prognostic features
invasive breast cancer among participants of a Canadian breast screening program: a
nested case-control study. Clin Breast Cancer 2011;11:27-32.
27 DeGroote R, Rush BF Jr, Milazzo J, Warden MJ, Rocko JM. Interval breast cancer: a
more aggressive subset of breast neoplasias. Surgery 1983;94:543-7.
28 Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten-to fourteen-year effect of screening
on breast cancer mortality. J Natl Cancer Inst 1982;69:349-55.
29 Hofvind S, Skaane P, Vitak B, Wang H, Thoresen S, Eriksen L, et al. Influence of review
design on percentages of missed interval breast cancers: a retrospect study of interval
cancers in a population-based screening program. Radiology 2005;237:437-43.
30 Hofvind S, Geller B, Skaane P. Mammographic features and histopathological findings
of interval breast cancers. Acta Radiol 2008;49:975-81.
31 Vitak B. Interval cancers in the Ostergötland Mammographic Screening Program:
radiological analysis. Eur Radiol 1998;8:639-46.
32 Domingo L, Sala M, Servitja S, Corominas JM, Ferrer F, Martínez J, et al. Phenotypic
characterizations and risk factors for interval breast cancers in a population-based breast
cancer screening program in Barcelona, Spain. Cancer Causes Control 2010;21:1155-64.
33 Vitak B, Olsen KE, Månson JC, Arnesson LG, Stål O. Tumor characteristics and survival
in patients with invasive interval breast cancer classified according to mammographic
findings at the latest screening: a comparison of true interval and missed interval cancers.
Eur Radiol 1999;9:460-9.
34 Porter GJR, Evans AJ, Burrell AJ, Lee AHS, Ellis IO, Chakrabarti J. Interval breast cancers:
prognostic features and survival by subtype and time since last screen. J Med Screen
2006;13:115-22.
Accepted: 1 November 2012
Cite this as: BMJ 2012;345:e7536
This is an open-access article distributed under the terms of the Creative Commons
Attribution Non-commercial License, which permits use, distribution, and reproduction in
any medium, provided the original work is properly cited, the use is non commercial and
is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-
nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e7536 doi: 10.1136/bmj.e7536 (Published 16 November 2012) Page 5 of 10
RESEARCHTables
Table 1| Characteristics of women with breast cancer in interval cancer group and in non-screened cancer group. Values are numbers
(percentages) unless stated otherwise
P value Non-screened cancer group (n=5300) Interval cancer group (n=1816) Characteristics
60.1 (7.1) 59.4 (5.7) Mean (SD) age at diagnosis (years)
Histological type:
<0.001 4176 (78.8) 1377 (75.8) Ductal
531 (10.0) 245 (13.5) Lobular
593 (11.2) 194 (10.7) Other
Tumour size*:
<0.001 2464 (59.9) 962 (56.1) 1 (<20 mm)
1344 (32.7) 574 (33.5) 2 (>20-50 mm)
106 (2.6) 137 (8.0) 3 (>50 mm)
197 (4.8) 42 (2.5) 4 (ingrowth)
1189 (22.4)† 101 (5.6)† Unknown
Nodal status*:
<0.001 2805 (58.7) 910 (54.4) Positive
2491 (41.3) 764 (45.6) Negative
520 (9.8)† 142 (7.8)† Missing
Stage‡:
<0.001 2607 (49.4) 750 (41.5) I
2236 (42.4) 913 (50.6) II
153 (2.9) 56 (3.1) III
279 (5.3) 87 (4.8) IV
<0.001 798 (15.0) 869 (47.9) Sentinel node biopsy
<0.001 1912 (36.1) 701 (38.6) Tamoxifen administered
<0.001 1307 (24.7) 246 (13.5) Total No of deaths
<0.001 979 (18.5) 194 (10.7) Deaths from breast cancer
*Based on pathological tumour, node, and metastasis classification.
21
†% of total breast cancers.
‡I, localised breast cancer; II, lymph node positive; III, growth into skin or chest wall; and IV, metastasis. Missing information on stage: 10 interval cancers and 25
non-screened cancers.
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RESEARCHTable 2| Tumour characteristics of interval breast cancers in six month intervals from last normal screening result to diagnoses. Values
are numbers (percentages) unless stated otherwise
Time since last normal screening result (months)
Characteristics 19-24 (n=584) 13-18 (n=554) 7-12 (n=497) 0-6 (n=181)
21.5 (13.4) 20.6 (12.5) 19.8 (11.8) 19.3 (12.2) Mean (SD) tumour size (mm)
304 (56.4) 267 (52.8) 253 (54.5) 86 (52.1) Node negative
45 (7.7) 48 (8.7) 33 (6.6) 16 (8.8) Missing node status*
130 (27.0) 92 (20.2) 81 (19.6) 35 (24.0) Grade I
213 (44.3) 214 (46.9) 206 (49.9) 67 (45.9) Grade II
138 (28.7) 150 (32.9) 126 (30.5) 44 (30.1) Grade III
103 (17.6) 98 (17.7) 84 (16.9) 35 (19.3) Missing grade*
Oestrogen receptor status:
245 (73.8) 251 (71.7) 224 (69.6) 92 (74.8) Positive†
87 (26.2) 99 (28.3) 98 (30.4) 31 (25.5) Negative‡
252 (43.2) 204 (36.8) 175 (35.2) 58 (32.0) Missing data*
Progesterone receptor status:
174 (53.2) 181 (53.2) 162 (51.1) 64 (52.9) Positive†
153 (46.8) 159 (46.8) 155 (48.9) 57 (47.1) Negative‡
257 (44.0) 214 (38.6) 180 (36.2) 60 (33.2) Missing data*
*% of total breast cancers.
†≥10% positive staining.
21
‡<10% positive staining.
21
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RESEARCHTable 3| Hazard ratios (95% confidence intervals) for breast cancer specific mortality between breast cancer groups overall and across
age categories
Age at diagnosis (years)
Overall
Variables
65-72 60-64 55-59 50-54
P
value
Hazard ratio
(95% CI)
P
value
Hazard ratio
(95% CI)
P
value
Hazard ratio
(95% CI)
P
value
Hazard ratio
(95% CI)
P
value
Hazard ratio*
(95% CI)
— 1 (reference)
(n=1672
cancers)
1 (reference)
(n=963 cancers)
1 (reference)
(n=1558
cancers)
1 (reference)
(n=1507
cancers)
1 (reference)
(n=5300
cancers)
Non-screened
cancer group
0.89 1.02 (0.76 to
1.37)
(n=410 cancers)
0.55 0.89 (0.61 to
1.30)
(n=399 cancers)
0.37 1.13 (0.86 to
1.49)
(n=578 cancers)
0.25 0.81 (0.57 to
1.16)
(n=429 cancers)
0.81 0.98 (0.84 to
1.15)
(n=1816
cancers)
Interval
cancer† group
Months since
last screen:
0.91‡ 1.12 (0.42 to
3.00)
0.78‡ 1.19 (0.44 to
3.21)
0.84‡ 1.61 (0.80 to
3.29)
0.61‡ 0.68 (0.28 to
1.65)
0.53‡ 1.09 (0.70 to
1.67)
0-6
0.97 (0.56 to
1.69)
0.82 (0.42 to
1.60)
1.19 (0.77 to
1.85)
0.81 (0.43 to
1.53)
0.97 (0.74 to
1.28)
7-12
1.01 (0.62 to
1.68)
1.37 (0.72 to
2.09)
1.04 (0.67 to
1.64)
1.00 (0.58 to
1.76)
1.06 (0.82 to
1.36)
13-18
1.04 (0.66 to
1.63)
0.52 (0.23 to
1.19)
1.04 (0.66 to
1.65)
0.66 (0.31 to
1.40)
0.87 (0.66 to
1.15)
19-26
*Age adjusted.
†Categorised as time since last normal mammogram (time since last screen) in six month intervals.
‡P for trend.
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RESEARCHTable 4| Age adjusted hazard ratios (95% confidence intervals) for breast cancer specific mortality among women with interval breast
cancers comparing screening round according to time since last normal screening result
P for trend
Time since last normal screening result (months)
Overall Screening round (No of cancers) 19-24 13-18 7-12 0-6
0.41 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (n=564)
0.72 1.48 (0.76 to 2.87) 0.55 (0.29 to 1.02) 1.06 (0.55 to 2.06) 0.85 (0.28 to 2·64) 0.89 (0.63 to 1.27) 2 (n=475)
0.85 1.18 (0.54 to 2.60) 0.39 (0.17 to 0.89) 1.18 (0.58 to 2.41) 1.07 (0.36 to 3·23) 0.86 (0.58 to 1.27) 3 (n=355)
0.74 1.65 (0.64 to 4.29) 0.43 (0.15 to 1.23) 0.66 (0.22 to 1.94) 0.32 (0.04 to 2·61) 0.69 (0.39 to 1.21) 4 (n=220)
0.17 — 1.39 (0.40 to 4.80) 0.38 (0.05 to 2.93) 1.19 (0.37 to 9·88) 0.99 (0.42 to 2.31) 5 (n=182)
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RESEARCHFigures
Fig 1 Cumulative breast cancer survival plot for women with breast cancer by group
Fig 2 Cumulative overall survival plot for women with breast cancer by group
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RESEARCH